Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A gender-related action of IFNbeta-therapy was found in multiple sclerosis.
Motor impairments at presentation of clinically isolated syndrome suggestive of multiple sclerosis: Characterization of different disease subtypes.
Chaperone activity of α B-crystallin is responsible for its incorrect assignment as an autoantigen in multiple sclerosis.
Fatigue in multiple sclerosis - A brief review.
Does glatiramer acetate provoke hepatitis in multiple sclerosis?
Characterization of human platelet binding of recombinant T cell receptor ligand.
Severe haematological complications during treatment with natalizumab.
Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial.
QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
MS and NMO: Partners No More.
Substance Name: Naltrexone
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.
Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study.
Incidence of multiple sclerosis in Northern Lisbon, Portugal: 1998¿2007.
Quantitative assessment of multiple sclerosis using inertial sensors and the TUG test.
Nav1.5 sodium channels in macrophages in multiple sclerosis lesions.
Association Between Multiple Sclerosis and Erectile Dysfunction: A Nationwide Case-Control Study.
Long-term follow-up of vanishing tumors in the brain: How should a lesion mimicking primary CNS lymphoma be managed?
Abnormalities of Motor Imagery and Relationship With Depressive Symptoms in Mildly Disabling Relapsing-Remitting Multiple Sclerosis.
Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon.
PLEGRIDY™ (peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis
Slowing of brain atrophy and reductions in new multiple sclerosis lesions sustained at three years in patients treated with Genzyme's LemtradaTM
High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation.
A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C.

Pages